Literature DB >> 14527955

Farnesoid X receptor activates transcription of the phospholipid pump MDR3.

Li Huang1, Annie Zhao, Jane-L Lew, Theresa Zhang, Yaroslav Hrywna, John R Thompson, Nuria de Pedro, Inmaculada Royo, Richard A Blevins, Fernando Peláez, Samuel D Wright, Jisong Cui.   

Abstract

The human multidrug resistance gene MDR3 encodes a P-glycoprotein that belongs to the ATP-binding cassette transporter family (ABCB4). MDR3 is a critical trans-locator for phospholipids across canalicular membranes of hepatocytes, evidenced by the fact that human MDR3 deficiencies result in progressive familial intrahepatic cholestasis type III. It has been reported previously that MDR3 expression is modulated by hormones, cellular stress, and xenobiotics. Here we show that the MDR3 gene is trans-activated by the farnesoid X receptor (FXR) via a direct binding of FXR/retinoid X receptor alpha heterodimers to a highly conserved inverted repeat element (a FXR response element) at the distal promoter (-1970 to -1958). In FXR trans-activation assays, both the endogenous FXR agonist chenodeoxycholate and the synthetic agonist GW4064 activated the MDR3 promoter. Deletion or mutation of this inverted repeat element abolished FXR-mediated MDR3 promoter activation. Consistent with these data, MDR3 mRNA was significantly induced by both chenodeoxycholate and GW4064 in primary human hepatocytes in time- and dose-dependent fashions. In conclusion, we demonstrate that MDR3 expression is directly up-regulated by FXR. These results, together with the previous report that the bile salt export pump is a direct FXR target, suggest that FXR coordinately controls secretion of bile salts and phospholipids. Results of this study further support the notion that FXR is a master regulator of lipid metabolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14527955     DOI: 10.1074/jbc.M308321200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

Review 1.  New perspectives for the treatment of cholestasis: lessons from basic science applied clinically.

Authors:  James L Boyer
Journal:  J Hepatol       Date:  2006-12-18       Impact factor: 25.083

Review 2.  Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein).

Authors:  Ronald P J Oude Elferink; Coen C Paulusma
Journal:  Pflugers Arch       Date:  2006-04-19       Impact factor: 3.657

3.  Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion.

Authors:  Nisanne S Ghonem; Meenakshisundaram Ananthanarayanan; Carol J Soroka; James L Boyer
Journal:  Hepatology       Date:  2014-01-27       Impact factor: 17.425

4.  Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters.

Authors:  Tristan M Sissung; Phoebe A Huang; Ralph J Hauke; Edel M McCrea; Cody J Peer; Roberto H Barbier; Jonathan D Strope; Ariel M Ley; Mary Zhang; Julie A Hong; David Venzon; Jonathan P Jackson; Kenneth R Brouwer; Patrick Grohar; Jon Glod; Brigitte C Widemann; Theo Heller; David S Schrump; William D Figg
Journal:  Mol Pharmacol       Date:  2019-06-07       Impact factor: 4.436

Review 5.  FXR and PXR: potential therapeutic targets in cholestasis.

Authors:  Johan W Jonker; Christopher Liddle; Michael Downes
Journal:  J Steroid Biochem Mol Biol       Date:  2011-07-20       Impact factor: 4.292

6.  Infection of primary hepatocytes with adenoviral vectors alters biliary lipid metabolism.

Authors:  Yuri Rueda; Itsaso Garcia-Arcos; Patricia Aspichueta; Begoña Ochoa; Lourdes Palacios; Olatz Fresnedo
Journal:  J Physiol Sci       Date:  2013-04-05       Impact factor: 2.781

7.  Activation of the farnesoid X receptor provides protection against acetaminophen-induced hepatic toxicity.

Authors:  Florence Ying Lee; Thomas Quad de Aguiar Vallim; Hansook Kim Chong; Yanqiao Zhang; Yaping Liu; Stacey A Jones; Timothy F Osborne; Peter A Edwards
Journal:  Mol Endocrinol       Date:  2010-06-23

8.  Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis.

Authors:  Sayeepriyadarshini Anakk; Mitsuhiro Watanabe; Scott A Ochsner; Neil J McKenna; Milton J Finegold; David D Moore
Journal:  J Clin Invest       Date:  2010-12-01       Impact factor: 14.808

Review 9.  FXR signaling in the enterohepatic system.

Authors:  Tsutomu Matsubara; Fei Li; Frank J Gonzalez
Journal:  Mol Cell Endocrinol       Date:  2012-05-17       Impact factor: 4.102

Review 10.  Recent developments in diagnostics and treatment of neonatal cholestasis.

Authors:  Amy G Feldman; Ronald J Sokol
Journal:  Semin Pediatr Surg       Date:  2020-07-23       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.